EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 1206)

[Knollebauer]

versteh nur echt nicht, wer da nachmittags aufsteht und innerhalb von 3 Tagen 100 k Stücke umsetzt und das für +- 3 Cents

[j.f.]

hi knolle,
kurze übersetzung bitte

gruß j.f.

[Knollebauer]

habt ihr das schon gelesen?

ASX RELEASE 6 April 2004 Final Pre-Clinical Milestone Attained for BrachySilTM Paves the way for first BioSiliconTM trial in Man Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that its Singaporean subsidiary, pSiOncology Pte Ltd has successfully completed a final pre-clinical study for its lead BioSiliconTM product, BrachySilTM. Following an earlier study in mouse tumour models, that successfully demonstrated the excellent efficacy of the BrachySilTM product, a study has been performed in a pig model successfully validating the fine gauge needle delivery method chosen for the upcoming Phase IIa human clinical trial, which is set to commence in May. This important and final pre-clinical milestone now paves the way for a ‘first in man’ evaluation of BioSiliconTM and BrachySilTM. These studies are important as they provide the radiologist involved in the upcoming trial with the necessary experience required before applying the technology to a patient. This recent large animal study demonstrated two important findings which are clearly evident in the images on the following page: • BrachySil™ is very well retained within liver tissue with little or no leakage of radioactivity into surrounding tissues or the blood stream. • BrachySilTM killed tissue within a very well-defined radius of application. This latter property is expected to provide significant benefits in the treatment of tumours that are associated with important healthy tissue (e.g. vasculature, nerves etc). pSivida’s Managing Director, Mr Gavin Rezos, said, “The results of this study clearly demonstrate the exceptional localization of the product resulting in the radioactivity being extremely well defined in the intended treatment region (thus minimizing side-effects); and secondly it validates the method of delivery to be utilized. BrachySilTM will be delivered via a fine gauge needle, making it a more user-friendly product for both patient and physician than some products currently in the marketplace. “The study is a necessary, final safety step before the first trials in Man and with the excellent tumor regression activity of the product demonstrated in previous trials, pSivida is now poised to begin its clinical development programme” “Meetings with European and Asian regulatory agencies have provided early indications that BrachySil™ may be treated as an implantable medical device, which potentially means a much shorter timeframe to market and sales.” The first human clinical study of BrachySil™ will be conducted in May in Singapore under the auspices of the Singapore General Hospital (SGH) and the National Cancer Centre (NCC) two of Singapore’s most progressive and advanced oncology centres. BrachySilTM, the Company’s lead product is targeted to the substantial brachytherapy market (currently $600 million and expected to exceed US$1 billion in 2005). Unlike many other approaches in the market, BrachySilTM is expected to be launched as a simple intratumoural implantable medical device for the selective regression of otherwise inoperable tumors. The first clinical trial is aimed at evaluating safety in patients with inoperable primary liver tumors. Second stage commercialization of the product will target other major cancers.


Gruß Knolle

[11eas]

http://www.psivida.com.au/

[11eas]

ast Price +/- % Open High Volume
$1.1700 $-0.0600 -4.9% 1.2000 1.2000 953,447

[covino02]

...den kurzen "absacker" von gestern haben wir doch wieder längst gutgemacht.

akt: 0,73

charttechnisch ist der ausbruch gelungen und wir laufen beständig nach oben.

was will man mehr

[leuchturm]

Da schläft heut auch alles!!

[Mambo6]

mir ist als wären alle aus lauter Panik ausgestiegen..

[frankiie]

favourit seit heute ist absolut:

3u telecom

hat gestern bekannt gegeben dass ein erneuter konkurrent übernommen worden ist und somit auch zugang ins voice over IP geschäft gelungen ist, absoluter trendmarkt, so wie bei
QSC und Broadnet Mediascape!

einsteigen solange es noch kurse unter 14 euro gibt

morgen hagelt es empfehlungen!!!

[Dr.Jones]

#800